About Careers MedBlog Contact us

Expanded Use of Glivec Approved by EU: Novartis

by Kathy Jones on February 28, 2012 at 7:46 PM
Font : A-A+

 Expanded Use of Glivec Approved by EU: Novartis

The European Union will allow an expanded use of the drug Glivec to treat certain rare forms of gastrointestinal cancer, Novartis has revealed.

The European Commission approved an update to the Glivec label to include 36 months of treatment after surgery "for adults with KIT (CD117)-positive gastrointestinal stromal tumors (GIST)," Novartis said in a statement.


"Gastrointestinal stromal tumors are a rare, life-threatening cancer of the gastrointestinal tract," it said.

They are often difficult to diagnose and treat because they may not cause physical symptoms.

The cancers are usually diagnosed in patients aged between 55 and 65, and are characterised by tumors of connective tissue supporting the digestive tract.

Last year Novartis said sales of Glivec reached $4.7 billion (3.5 billion euros).

Source: AFP
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Expanded Use of Glivec Approved by EU: Novartis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests